8 completed, 6 unknown, 5 terminated, 2 active not recruiting. 12 Phase 2, 6 Phase 1, 3 Not applicable, 3 Phase 3.
Follow Acute-graft-versus-host Disease: new trials by email Literature Review of Acute-graft-versus-host Disease trials Research Report on Acute-graft-versus-host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) ASC930 - Acute-graft-versus-host Disease | Phase 2 | Unknown | ASC Therapeutics | 60 | 2023-12-01 | 2023-07-20 |
| Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 10 | 2023-06-05 | 2026-03-24 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| Safety and Tolerability of FMT Capsules in Healthy Volunteers XBI-302, XBI-302 Placebo - Acute-graft-versus-host Disease | Phase 1 | Unknown | Shenzhen Xbiome Biotech Co., Ltd. | 36 | 2022-04-21 | 2022-05-06 |
| Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial Exercise, Attention control - Graft Vs Host Disease, Acute-graft-versus-host Disease | Not applicable | Active not recruiting | Dana-Farber Cancer Institute | 36 | 2022-04-14 | 2026-10-26 |
| Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation Sitagliptin + Standard Prophylaxis, Standard Prophylaxis - Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 190 | 2021-12-22 | 2026-02-10 |
| Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease Ruxolitinib - Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease | Phase 1 | Completed | Children's Hospital Medical Center, Cincinnati | 13 | 2021-10-27 | 2024-01-16 |
| HBOT in the Treatment and Prevention of aGVHD Hyperbaric oxygen therapy - Hyperbaric Oxygen Therapy, Acute-graft-versus-host Disease | Not applicable | Unknown | Shandong Provincial Hospital | 100 | 2021-10-10 | 2021-10-14 |
| Abatacept s.c. for aGVHD Prevention in Haplo-HCT Abatacept s.c. - Abatacept, Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 29 | 2021-06-01 | 2026-06-11 |
| Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation hAECs - Acute-graft-versus-host Disease | Not applicable | Unknown | Peking University People's Hospital | 27 | 2020-07-01 | 2020-10-01 |
| Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease Uvadex - Acute-graft-versus-host Disease | Phase 2 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 24 | 2020-05-18 | 2025-03-30 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation RGI-2001, Standard of Care - Graft Vs Host Disease, Graft-versus-host-disease | Phase 2 | Completed | Regimmune Corporation | 49 | 2019-11-25 | 2024-05-28 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | CSL Behring | 222 | 2019-03-27 | 2026-09-09 |
| UCMSCs as Front-line Approach of Treatment for Patients With aGVHD Umbilical cord derived mesenchymal stem cell, Placebo - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | Cytopeutics Sdn. Bhd. | 26 | 2019-02-01 | 2026-01-02 |
| A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease Methoxsalen + ECP device, Corticosteroids - Acute-graft-versus-host Disease | Phase 2 | Unknown | Central Hospital, Nancy, France | 78 | 2018-10-01 | 2018-07-30 |
| Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies Blood Sample, Stool Sample, Urine Sample - Immune and Microbial Reconstitution, Systemic Viral Infection | Terminated | Masonic Cancer Center, University of Minnesota | 210 | 2018-09-21 | 2023-08-21 | |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) Defibrotide, Standard of Care - Graft-versus-host Disease, Acute-graft-versus-host Disease | Phase 2 | Completed | Jazz Pharmaceuticals | 152 | 2018-02-21 | 2021-08-18 |
| FMT in Gut aGVHD Treated Fecal microbiota - Acute-graft-versus-host Disease | Recruiting | The First Affiliated Hospital of Soochow University | 50 | 2017-05-16 | 2026-06-01 | |
| Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease Cannabidiol, Methylprednisolone, Calcineurin inhibitor - Acute-graft-versus-host Disease | Phase 2 | Unknown | moshe yeshurun | 10 | 2015-04-01 | 2015-03-19 |
Showing 20 of 23. Sign in to see all of them.
Graft vs Host Disease (6) · Bronchiolitis Obliterans Syndrome (3) · Cytokine Release Syndrome (1) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · alpha 1-Antitrypsin Deficiency (1) · alpha-1-Antitrypsin Deficiency, Autosomal Recessive (1)
Immune System Diseases (9) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Bronchial Diseases (3) · Bronchiolitis (3) · Bronchiolitis Obliterans (3) · Bronchitis (3) · Lung Diseases, Obstructive (3) · Organizing Pneumonia (3) · Graft vs Host Disease (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Emphysema (1)
Adrenal Cortex Hormones (2) · Methoxsalen (2) · Methylprednisolone (2) · Standard of Care (2) · alpha 1-Antitrypsin (2) · itolizumab (2) · ruxolitinib (2) · Blood Specimen Collection (1) · Calcineurin Inhibitors (1) · Cannabidiol (1) · Carmustine (1) · Chorionic Gonadotropin (1) · Cyclophosphamide (1) · Cyclosporine (1) · Etoposide (1)
The First Affiliated Hospital of Soochow University (3) · Masonic Cancer Center, University of Minnesota (2) · ASC Therapeutics (1) · Biocon Limited (1) · CSL Behring (1) · Central Hospital, Nancy, France (1) · Children's Hospital Medical Center, Cincinnati (1) · Cytopeutics Sdn. Bhd. (1) · Dana-Farber Cancer Institute (1) · Equillium (1) · Impatients N.V. trading as myTomorrows (1) · Jazz Pharmaceuticals (1) · Lee Dupuis (1) · Peking University People's Hospital (1) · Regimmune Corporation (1)
United States (10) · China (6) · Germany (4) · Canada (3) · Italy (3) · Spain (3) · Australia (2) · Austria (2) · Belgium (2) · France (2) · Israel (2) · Portugal (2) · South Korea (2) · Bulgaria (1) · Croatia (1)
Christina Dieli-Conwright (1) · Fang Hou, MD (1) · Francis A. Ayuk, Prof. Dr. (1) · Joel Rothman (1) · Laura Johnston (1) · Lee Dupuis, PhD (1) · Pooja Khandelwal, MD (1) · Sen Mui Tan (1) · Sherman Holtan, MD (1) · Suning Chen, Professor (1) · Xiaojun Huang (1) · Xiaoming Zhou, Dr. (1) · Yi-Bin Chen, MD (1)
PMID 30319644, PMID 34220825, PMID 35484649, PMID 36352455, PMID 36519326, PMID 38802569, PMID 40680268
2017 (1), 2018 (1)